Free Design Audit Available - Click Here for Details

Perfuze® Announces FDA Clearances for Novel Neurovascular Aspiration and Access Catheters for Stroke Treatment

ALWAY, Ireland--(BUSINESS WIRE)-- Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, proudly announces FDA clearance for the Millipede 070 Aspiration Catheter and the 2nd generation of the Millipede 088 Access Catheter.

The Millipede 070 Aspiration Catheter is built upon a pioneering, distinctive technology that enables physicians to address critical unmet needs in ischemic stroke treatment. It is designed to remove clots rapidly and safely. This novel, unique catheter is designed for superior deliverability and high procedural efficiency, making it a more refined approach for restoring blood flow to the brain during endovascular thrombectomy procedures.

“In our initial experience with Millipede 070, the system easily delivered to the target occlusion allowing rapid, effective and safe reperfusion,” stated David Fiorella, Director of the Stony Brook Cerebrovascular Center, NY, USA. Millipede 070 has a unique design with a rib-and-recess surface architecture designed to improve navigability and reduce tip stiffness, while maintaining durability.

“Perfuze aims to provide neurovascular interventionists with innovative thrombectomy solutions, to maximize their opportunity to completely restore blood flow to the brain on their first attempt,” said Wayne Allen, CEO of Perfuze. “The 510(k) clearance for the Millipede 070 Aspiration Catheter is a key addition to our portfolio of products and is designed to simplify removal of the clot and improve clinical outcomes.”

Sign up for Blog Updates